Few experiences of peripheral blood (PB) hematopoietic stem cell mobilization for autologous transplantation have been reported to date in children with acute leukemia (AL). The five-drug-chemotherapy 'DIAVE' (dexamethazone, idarubicine, cytosine-arabinoside, vincristine, etoposide), followed by G-CSF, previously reported as consolidation, was adopted as a mobilization /l) at a median of 12 days. In conclusion, the DIAVE regimen compares favorably with conventional mobilizing regimens, usually containing cyclophosphamide, in terms of low toxicity, collection time predictability, and efficacy, as shown by the high proportion of patients mobilizing, the large amounts of stem cell collected by means of one or two leukaphereses only, and the prompt engraftment after infusion.
Childhood acute leukemia (AL) is a disease potentially curable using chemotherapy alone. Nevertheless, hematopoietic stem cell (HSC) transplantation is a treatment option, whenever conventional chemotherapy is expected to have high probability of failure. [1] [2] [3] When a compatible related donor is not available, it is still controversial when highdose chemotherapy followed by autologous HSC rescue or allogeneic transplantation from an alternative donor should be undertaken, according to the prognosis of the disease. 4, 5 For children with acute lymphoblastic leukemia (ALL) in second complete remission (CR2) after a late relapse or with acute non-lymphoblastic leukemia (ANLL) in first CR (CR1) the prognosis is not usually so dismal as to make allogeneic transplantation from an alternative donor acceptable, due to the transplant-related morbidity and mortality rates which are still high. High-dose chemotherapy followed by autologous stem cell rescue may then be considered as an alternative to 'conventional' chemotherapy. [2] [3] [4] In most cases the preferred source of autologous HSC is peripheral blood (PB), stimulated by using various mobilizing regimens, usually consisting of high-dose cyclophosphamide, followed by granulocyte colony-stimulating factor (G-CSF). 6, 7 The collection of large doses of HSC allows purification procedures, aiming at achieving complete removal of possibly contaminating leukemic cells. 8, 9 Even though autologous transplantation is widely used in adults, limited experiences of PB mobilization have been reported so far in children, other than in solid tumors. 10, 11 In this study we report on the effectiveness of the new regimen 'DIAVE' in children with AL in terms of the high proportion of patients 'mobilizing' and high level of 'mobilized stem cells'.
Patients and methods
From January 1995 to June 2001, 34 children with AL were considered eligible for PB HSC collection and autologous transplantation at a single institution, according to the guidelines of the Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP), which suggest high-dose chemotherapy and autologous HSC rescue for ALL patients in CR2 if relapse occurred late (Ͼ30 months) after the onset and high-risk ANLL in CR1, whenever a compatiblerelated donor is lacking. Twelve patients of this series were previously reported. 9 Twenty-three patients with ALL in CR2 (21) or CR3 (2) and six patients with ANLL in CR1 (20 males; median age: 8 years, range: 3-21; median weight: 34 kg, range: 15-73), received the 'DIAVE' regimen to mobilize HSC; five patients were treated according to different schedules and were not included in this report. The mobilizing regimen was scheduled after induction and consolidation. The median interval between CR1 and relapse was 38 months (range: 15-90) for ALL patients. The median interval between last CR and the beginning of the mobilizing regimen was 4 months (range: 2-7) for all patients.
The mobilizing regimen DIAVE was adopted to consolidate remission and mobilize HSC, according to a postremission strategy for adult ALL; 12 it consisted of a fivedrug-chemotherapy (dexamethazone 5 mg/m 2 for 7 days, idarubicin 10 mg/m 2 and cytosine-arabinoside 3 g/m 2 on day 1; vincristine 1.5 mg/m 2 and etoposide 450 mg/m 2 on day 2) administered over a 24-h in-patient admission, followed by G-CSF (10 g/kg s.c. daily from day 5). From day 10, the absolute number of CD34 + cells was monitored daily in the PB, by flow cytometry with fluorescein isothiocyanate-conjugated murine monoclonal antibodies against human CD34 antigen and a FACScan analyzer (Becton Dickinson, Mountain View, CA, USA). Mobilization was considered successful if a peak of at least 0.04 ϫ 10 9 /l CD34 + cells was reached in the PB. Once the threshold was approached, the leukapheresis was performed through a central venous catheter and temporary peripheral veinous access, by means of a continuous flow cell separator (COBE Spectra, Lakewood, CO, USA). Approximately 2.5 patient-blood volumes were processed to obtain at least 5 ϫ 10 6 CD34 + cell/kg. If necessary, a second leukapheresis was performed the following day. 13, 14 In order to prevent clotting, ACD was used at a ratio of 1:12 for children weighing 25 kg or more; for children under 25 kg, 1:16 ACD was combined with heparin 50 U/kg, and the separator was initialized with a compatible filtered and irradiated red blood cell unit, suspended in 4% albumin, up to the patient's hematocrit, to avoid transient hypovolemia, due to the volume sequestered in the separator. 15 It was common practice to collect large CD34 + cell amounts in order to allow purification and storage of an unmanipulated fraction of the CD34 + cells collected, to be used for rescue in the event of purification procedure failure or of non-engrafment. Recovery of 70% of CD34
+ cells was expected after immunological purification, which was performed by means of CD34 + negative selection for ALL patients.
9 CD34 + positive selection was adopted for some patients with ANLL whose blasts did not express the CD34 antigen, in an attempt to obtain a virtually leukemia-free product. Final products were cryopreserved as previously described. 16, 17 
Results
No toxicity was reported during the DIAVE administration; 60% of the patients experienced severe pancytopenia (ANC Ͻ0.5 ϫ 10 9 /l) afterwards, but only 20% required hospitalization for fever; no severe infections occurred. A median peak of 94 ϫ 10 6 CD34 + cells/l (range: 10-604) was reached at a median time of 12 days (range: 10-18) after the beginning of the mobilizing regimen, when the median WBC count in PB was 14 (1-47) ϫ 10 9 /l. In all but two patients CD34
+ cells peaked between 10 and 14 days after the beginning of the DIAVE. Mobilization was successful in 86% (25/29) of the patients receiving the DIAVE regimen; in particular 20 of the 21 patients with ALL in CR2 (95%) and five of the six patients with AML (83%), but neither of the two patients with ALL in CR3 mobilized enough HSC. The four 'non-mobilizing' patients, who reached a median peak of 25 (range: 10-35) ϫ 10 6
CD34
+ cells/l, underwent autologous transplantation with bone marrow. All collection procedures were well tolerated; only mild hypocalcemia-related symptoms, promptly responding to small i.v. boluses of calcium gluconate, were reported. Two children required mild sedation per os to perform the leukapheresis, mostly to maintain the peripheral venous access. Priming of the cell separator was needed for five patients. In five of 25 patients a second leukapheresis was necessary the following day. A median of 2.5 blood volumes per procedure were processed and a median of 10.9 (range: 2.4-56.6) ϫ10 6 CD34 + cells/kg were collected. Patients with ANLL in CR1 mobilized more cells than patients with ALL in CR2; characteristics of HSC collections according to disease type are shown in Table 1 . For all but one patient a fraction of the CD34 + cells was stored unmanipulated as a rescue. The fraction to be infused underwent immunological purification after collection by means of negative (17 ALL) or positive selection (4 ANLL), or was stored unmanipulated in four patients because it had been collected prior to the adoption of the purification protocol (3 ALL) or as a rescue before a partially incompatible unrelated donor transplant (1 ANLL). One patient (ALL) refused transplantation and 23 patients were actually transplanted with PB HSC; all engrafted after receiving a median of 5. + cells detected in the PB for all patients (r = 0.8670); the number of CD34 + cells collected was higher for ANLL patients, and not correlated with age and weight, when corrected for diagnosis (Table 1) . A negative correlation between time from CR1 to mobilization was observed in the ANLL patients (r = Ϫ0.8670).
415 Table 1 Cell counts in peripheral blood (PB) on the first day of collection and in the leukapheresis in the 25 patients who actually underwent PB HSC collection for acute lymphoblastic leukemia (ALL) or acute non lymphoblastic leukemia (ANLL) 
Discussion
In the present study, the five-drug regimen 'DIAVE' was effective in 86% of all treated children and in particular in 95% of the patients with ALL in CR2, yielding a high number of CD34 + cells, allowing both purification procedures and storing of unmanipulated fractions for rescue. Previous reports confirmed that dose-intensive regimens resulted in superior HSC mobilization than less intensive chemotherapy; 9 in fact, the DIAVE regimen had the advantage of serving both as consolidation chemotherapy and as a mobilizing regimen, before transplant. 9 The exclusion of highdose cyclophosphamide, included in most mobilization protocols, made its adoption easier shortly afterwards, as part of the conditioning regimen. DIAVE toxicity was quite acceptable, since admission for neutropenic fevers occurred in only 20% of the patients. After the low number of leukaphereses needed, crucial in a pediatric population, all products infused ensured prompt engraftment. The high predictivity of a 5-day span for collection was an advantage in the planning phase. Consistent with other reports, the cumulative myelotoxicity of the drugs previously administered to patients over their disease course seemed to play a role in jeopardizing the yield after mobilization. [18] [19] [20] According to the phase of the disease, patients with ANLL in CR1, who are less heavily treated, were 'better mobilizers', as compared to patients with ALL in CR2, while patients with ALL in CR3 did not mobilize at all. Moreover, the longer the treatment phase before mobilization, the lower the yield for ANLL patients in CR1.
In conclusion, we believe that the DIAVE regimen can be successfully adopted as mobilizing chemotherapy in childhood AL, due to its good expected anti-leukemic activity and low toxicity, the high proportion of patients who mobilized, the good predictability of collection time, and mostly the high CD34 + yields.
